Senseonics控股 SENS 深 沪
已收盘 02-06 16:00:00 美东时间
7.43
+0.520
+7.53%
华盛通- 最 高7.545
- 今 开7.01
- 成交量 52.08万股
- 最 低 6.78
- 昨 收 6.91
- 总市值 3.04亿
- 52周最高 25.60
- 市盈率 静 --
- 换手率 1.27%
- 52周最低 5.25
- 委 比 -24.53%
- 总股本 4085.85万
- 历史最高 111.20
- 量 比 0.87
- 振 幅 11.07%
- 历史最低 5.00
- 每 手 1
- 风险率 3.74%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Senseonics Receives CE Mark Approval For Eversense 365 CGM System
Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today
01-30 05:01
Senseonics Receives European Approval for Eversense 365, World’s Longest-lasting Continuous Glucose Monitor
Senseonics' Eversense 365 CGM system, the first and only one-year implantable glucose monitor, receives CE Mark approval for EU commercialization. Offering continuous glucose monitoring for up to 365 days, it reduces sensor changes and enhances accuracy, improving diabetes management. Company plans expansion in Germany, Italy, Spain, and Sweden, aiming to boost revenue and address European diabetes patients.
01-29 21:01
Senseonics Holdings to Participate in BTIG Annual MedTech Conference
Senseonics Holdings to Participate in BTIG Annual MedTech Conference Senseonics Holdings Inc., a medical technology company specializing in long-term implantable continuous glucose monitoring systems, will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools C
01-29 05:05
Senseonics Reports Record 2025 Revenue and Growth Milestones
Senseonics Holdings ( ($SENS) ) has issued an update. On January 12, 2026, Sens...
01-12 21:56
Senseonics reports preliminary unaudited revenue Q4 revenue of ~$14.2M
Senseonics (SENS) on Monday said that its preliminary unaudited Q4 2025 revenue was ~$14.2 million, while its preliminary unaudited annual revenue was ~$35.2 million. The company said it achieved 103%...
01-12 21:52
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System
Senseonics and Sequel MedTech have launched the integration of their products, combining the Eversense 365 CGM and the twiist AID system. This collaboration marks the first use of the world’s only one-year CGM with an AID system, offering patients a new level of flexibility and personalization in diabetes management. The Eversense 365 CGM provides exceptionally accurate monitoring for up to one year, while the twiist AID system uses iiSure techno...
01-08 21:01
Senseonics Acquires Eversense U.S. Assets, Reshapes Partnership
Senseonics Holdings ( ($SENS) ) has issued an announcement. On December 31, 202...
01-02 20:28
VistaGen appoints Nick Tressler as CFO
Vistagen (VTGN) on Monday announced the appointment of Nick Tressler as Chief Financial Officer (CFO), effective December 1, 2025. Most recently, he served as CFO of DYNEX Technologies, and before th...
2025-12-01 21:45
Senseonics announces transfer to Nasdaq
Senseonics (NYSE:SENS) announced on Monday that it will transfer the listing of its common stock from the NYSE to the NASDAQ effective after the market closes on November 14, 2025. The company’s stoc...
2025-11-10 22:11
Senseonics Announces Transfer to Nasdaq Stock Exchange
Senseonics Holdings, Inc. announced it will transfer its common stock listing from the NYSE American to the Nasdaq Global Select Market effective after the market closes on November 14, 2025. The stock will begin trading on Nasdaq under the ticker symbol "SENS" on November 17, 2025. The company, focused on developing long-term implantable continuous glucose monitoring systems for people with diabetes, aims to enhance its visibility and liquidity ...
2025-11-10 13:00
